DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD) MARKET ANALYSIS

Disease-Modifying Antirheumatic Drug (DMARD) Market, by Drug Type (Synthetic (sDMARD), (Conventional synthetic (csDMARDs), (Methotrexate, Sulfasalazine, Leflunomide, Hydroxychloroquine and Gold Salts), Targeted synthetic DMARDs (tsDMARDs), Biological DMARDs (bDMARD), (Original DMARDs (boDMARDs), Biosimilar DMARDs (bsDMARDs), (Primary, Secondary and Tertiary) and Others), by Route of Administration (Oral, Parenteral and Others), by Indication (Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Systemic Lupus Erythematosus and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Aug 2022
Code : CMI5185
Pages :156
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Increasing product launches for the treatment of rheumatoid arthritis, psoriasis, etc., are expected to drive the market growth during the forecast period

Increasing product launches for the treatment of rheumatoid arthritis, psoriasis which is expected to drive the global disease-modifying antirheumatic drug (DMARD) market growth during the forecast period. For instance, in November 2020, Cumberland Pharmaceuticals Inc., a U.S. specialty pharmaceutical company, announced the launch of RediTrex injection. RediTrex is a new line of pre-filled syringes specifically designed for ease of handling and dosing accuracy for the subcutaneous administration of methotrexate in patients with rheumatoid arthritis and psoriasis.